Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 1 Assessment of Antianginal Effects in the MERLIN-TIMI 36 Trial
Selected efficacy end points in the MERLIN-TIMI 36 trial. Based on Kaplan-Meier cumulative incidence (%) at 12 months. Primary end point: cardiovascular (CV) death/myocardial infarction (MI)/recurrent ischemia (RI). *p = 0.11;  p = 0.03;  p = 0.023. Blue bars = ranolazine (n = 3,279); yellow bars = placebo (n = 3,281).
|
